Tirabrutinib

Name: Tirabrutinib in Primary central nervous system lymphoma: Clinical presentation - signs and symptoms
Published: 2026-09-14T15:39:06-04:00

Primary central nervous system lymphoma

Manufacturer: Deciphera Pharmaceuticals
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the fiscal year ending March 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Clinical presentation - signs and symptoms

4 evidence topics · 1 source

Neurological and gastrointestinal symptoms: headache, seizures, nausea, and vomiting

“Signs and symptoms of primary CNS lymphoma may include nausea and vomiting or seizures.” (opens the source at this quote in a new tab)
“Headaches.” (opens the source at this quote in a new tab)

Motor symptoms: limb weakness

“Arm or leg weakness.” (opens the source at this quote in a new tab)

Cognitive symptoms: confusion

“Confusion.” (opens the source at this quote in a new tab)

Visual and auditory symptoms

“Double vision.” (opens the source at this quote in a new tab)
“Hearing loss.” (opens the source at this quote in a new tab)